Mr Callahan is a founding director of Orthocell. Mr Callahan is an experienced life sciences executive based in Philadelphia, USA. He has been the founding CEO or Executive Director of pharmaceutical and health tech companies including iCeutica Inc, Churchill Pharma Inc, Dimerix Biosciences, Emyria Ltd and Botanix Pharmaceuticals. He has led the development of four products that have received FDA approval and he has more than 25 years legal, IP and investment management experience. Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, clean technology and other sectors, and was General Manager and General Counsel with Australian listed technology and licensing company iPernica (Nearmap).

Dr Washer has 25 years of CEO and board experience in medical and agri-food biotech companies. He is Chairman of Emyria Ltd, director of Botanix Pharmaceuticals Ltd and current Director of Cynata Therapeutics Ltd. Stewart has held a number of Board positions in the past, including Chairman of Hatchtech Pty Ltd and was a director of iCeutica that was sold to a US Pharma. He was also a Senator with Murdoch University and was a Director of AusBiotech Ltd.

Professor Lidgren has authored and co-authored over 450 original publications and has more than 150 patents/applications. He was spokesman for Biomaterials in the Nordic Orthopaedic Society, Chairman for the Swedish National Knee Register, Director of the National Board of Health and Welfare, Musculoskeletal Competence Centre, and member of several editorial boards. Professor Lidgren initiated and has led the UN ratified Bone and Joint Decade and founded Scandimed. Professor Lidgren is the inventor, founder and board member of Bone Support and Director of Curando Nordic.

Mr Zhou has over 16 years' experience within China as a senior business manager & executive. Mr Zhou is the founding CEO of Shenzhen Lightning Digital Technology Co Ltd. Mr Zhou has experience within the public markets in Hong Kong, China & Taiwan and brings to the Board business management & development experience. Mr Zhou also has connections and experience in the licensing of technologies into the Asian region.

Mr Anderson has over 20 years' experience in the medical device and regenerative medicine fields with experience in bridging the gap between research and clinical practice in the development of emerging medical technologies. He also has experience in the establishment of GMP manufacturing facilities and scale-up activities for cell therapies and biological medical devices, and the associated regulatory filings. Mr Anderson has a track record with over 16 years' experience in CEO and board roles. His knowledge of the regenerative medicine fields compliments his insight and know-how in taking biological therapies from research to clinical applications and market introduction.

Ms Wise is an experienced board member with track record in medical device technologies and the life science industry including regulatory and market access strategies and commercialisation of Large and SMEs to the next level of growth and expansion. Leslie's 18-year record of accomplishment has given her a range of experience including market access, business strategy, product development, clinical trial design, reimbursement strategy and global commercialisation.

-

-